$CAPR
CAPRICOR THERAPEUTICS, INC.

2023 Q1 Form 10-K Financial Statement

#000155837023004124 Filed on March 17, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $2.987M $2.600M $2.551M
YoY Change 941.85%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.510M $2.794M $10.43M
YoY Change 29.24% 32.06% 37.04%
% of Gross Profit
Research & Development $7.700M $6.232M $21.80M
YoY Change 50.98% 485.96% 60.29%
% of Gross Profit
Depreciation & Amortization $230.1K $191.6K $533.1K
YoY Change 148.78% 143.61% 116.99%
% of Gross Profit
Operating Expenses $11.17M $9.026M $32.25M
YoY Change 42.65% 183.88% 52.24%
Operating Profit -$8.185M -$29.70M
YoY Change 4.51% 41.83%
Interest Expense $416.4K $379.7K $521.5K
YoY Change 2998.51% 2276.1% 807.66%
% of Operating Profit
Other Income/Expense, Net $416.4K $0.00 $677.9K
YoY Change 2998.53% -100.0% -25.99%
Pretax Income -$7.768M -$7.721M -$29.02M
YoY Change -0.64% 24.72% 44.93%
Income Tax
% Of Pretax Income
Net Earnings -$7.768M -$7.721M -$29.02M
YoY Change -0.64% 24.72% 44.93%
Net Earnings / Revenue -260.1% -296.96% -1137.37%
Basic Earnings Per Share -$0.31 -$1.18
Diluted Earnings Per Share -$0.31 -$0.31 -$1.18
COMMON SHARES
Basic Shares Outstanding 25.26M 25.24M 24.55M
Diluted Shares Outstanding 25.25M 24.55M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $45.17M $41.42M $41.42M
YoY Change -22.56% 18.74% 18.74%
Cash & Equivalents $10.61M $9.603M $9.603M
Short-Term Investments $34.57M $31.82M $31.82M
Other Short-Term Assets $875.1K $919.9K $919.9K
YoY Change -7.23% -20.7% -20.7%
Inventory
Prepaid Expenses
Receivables $547.6K $547.6K $547.6K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $46.59M $42.89M $42.89M
YoY Change -21.87% 17.71% 17.71%
LONG-TERM ASSETS
Property, Plant & Equipment $4.811M $4.588M $6.938M
YoY Change 106.61% 155.5% 50.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $268.2K $268.2K $268.2K
YoY Change -2.74% -2.74% -2.74%
Total Long-Term Assets $7.269M $7.206M $7.206M
YoY Change 37.47% 47.26% 47.26%
TOTAL ASSETS
Total Short-Term Assets $46.59M $42.89M $42.89M
Total Long-Term Assets $7.269M $7.206M $7.206M
Total Assets $53.86M $50.09M $50.09M
YoY Change -17.03% 21.21% 21.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.426M $4.924M $4.924M
YoY Change 32.39% 32.51% 32.51%
Accrued Expenses $693.7K $682.0K $682.0K
YoY Change 39.18% 63.31% 63.31%
Deferred Revenue $31.01M $17.98M
YoY Change 219.72%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $37.13M $23.59M $23.59M
YoY Change 159.24% 470.63% 470.63%
LONG-TERM LIABILITIES
Long-Term Debt $3.376M $3.376M $3.376M
YoY Change 0.0% 0.0% 0.0%
Other Long-Term Liabilities $7.149M $11.35M $11.35M
YoY Change -68.34% 362.59% 362.59%
Total Long-Term Liabilities $10.53M $14.72M $14.72M
YoY Change -59.45% 152.57% 152.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $37.13M $23.59M $23.59M
Total Long-Term Liabilities $10.53M $14.72M $14.72M
Total Liabilities $47.66M $38.31M $38.31M
YoY Change 18.32% 284.54% 284.54%
SHAREHOLDERS EQUITY
Retained Earnings -$144.8M -$137.1M
YoY Change 25.0% 26.85%
Common Stock $151.0M $148.8M
YoY Change 7.43% 6.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.206M $11.79M $11.79M
YoY Change
Total Liabilities & Shareholders Equity $53.86M $50.09M $50.09M
YoY Change -17.03% 21.21% 21.21%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$7.768M -$7.721M -$29.02M
YoY Change -0.64% 24.72% 44.93%
Depreciation, Depletion And Amortization $230.1K $191.6K $533.1K
YoY Change 148.78% 143.61% 116.99%
Cash From Operating Activities $4.210M -$6.902M $4.917M
YoY Change -82.49% 22.65% -129.25%
INVESTING ACTIVITIES
Capital Expenditures $347.7K $1.222M $2.000M
YoY Change -38.75% -431.6% 67.2%
Acquisitions
YoY Change
Other Investing Activities -$2.759M $6.365M -$31.71M
YoY Change
Cash From Investing Activities -$3.212M $5.142M -$35.07M
YoY Change 413.58% -1494.77% 2831.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $4.804M
YoY Change -76.19%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.895K 2.950M 4.874M
YoY Change -85.82% 6861.36% -75.9%
NET CHANGE
Cash From Operating Activities 4.210M -6.902M 4.917M
Cash From Investing Activities -3.212M 5.142M -35.07M
Cash From Financing Activities 3.895K 2.950M 4.874M
Net Change In Cash 1.002M 1.190M -25.28M
YoY Change -95.73% -119.98% -1239.14%
FREE CASH FLOW
Cash From Operating Activities $4.210M -$6.902M $4.917M
Capital Expenditures $347.7K $1.222M $2.000M
Free Cash Flow $3.862M -$8.125M $2.916M
YoY Change -83.55% 54.49% -116.2%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.18
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24552688
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23089323
CY2022 capr Class Of Warrant Or Right Exercised Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice
0.00
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001133869
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25241402
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24185001
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25241402
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-34058
CY2022 dei Entity Registrant Name
EntityRegistrantName
CAPRICOR THERAPEUTICS, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0363465
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
10865 Road to the Cure, Suite 150
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2022 dei City Area Code
CityAreaCode
858
CY2022 dei Local Phone Number
LocalPhoneNumber
727-1755
CY2022 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2022 dei Trading Symbol
TradingSymbol
CAPR
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
82668886
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25255154
CY2022 dei Auditor Firm
AuditorFirmId
468
CY2022 dei Auditor Name
AuditorName
Rose, Snyder & Jacobs LLP
CY2022 dei Auditor Location
AuditorLocation
Encino, California
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9603242
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34885274
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
31818020
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0
CY2022Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
547580
CY2021Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
391750
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
919892
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1159937
CY2022Q4 us-gaap Assets Current
AssetsCurrent
42888734
CY2021Q4 us-gaap Assets Current
AssetsCurrent
36436961
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4588030
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1795696
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2349974
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2821944
CY2022Q4 us-gaap Other Assets
OtherAssets
268172
CY2021Q4 us-gaap Other Assets
OtherAssets
275722
CY2022Q4 us-gaap Assets
Assets
50094910
CY2021Q4 us-gaap Assets
Assets
41330323
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4834683
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3116371
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
89234
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
599388
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
682039
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
417632
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
17980599
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23586555
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4133391
CY2022Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
3376259
CY2021Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
3376259
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1878070
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2452707
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
9467932
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
0
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
14722261
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5828966
CY2022Q4 us-gaap Liabilities
Liabilities
38308816
CY2021Q4 us-gaap Liabilities
Liabilities
9962357
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25241402
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24185001
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
25241
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
24185
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
148735420
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
139404060
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
105244
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-137079811
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108060279
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11786094
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
31367966
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50094910
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41330323
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2551469
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
244898
CY2022 us-gaap Revenues
Revenues
2551469
CY2021 us-gaap Revenues
Revenues
244898
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21816949
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13571045
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10431903
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7612295
CY2022 us-gaap Operating Expenses
OperatingExpenses
32248852
CY2021 us-gaap Operating Expenses
OperatingExpenses
21183340
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-29697383
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-20938442
CY2022 us-gaap Other Income
OtherIncome
190582
CY2021 us-gaap Other Income
OtherIncome
548207
CY2022 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
521535
CY2021 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
57460
CY2022 capr Debt Instrument Forgiveness Of Debt
DebtInstrumentForgivenessOfDebt
0
CY2021 capr Debt Instrument Forgiveness Of Debt
DebtInstrumentForgivenessOfDebt
318160
CY2022 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-34266
CY2021 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-7905
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
677851
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
915922
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-29019532
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-20022520
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
105244
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28914288
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20022520
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.18
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24552688
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23089323
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
28199784
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
20174448
CY2021 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
22430
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2965692
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28132
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-20022520
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
31367966
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4803534
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4458578
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
70304
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
105244
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-29019532
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11786094
CY2022 us-gaap Profit Loss
ProfitLoss
-29019532
CY2021 us-gaap Profit Loss
ProfitLoss
-20022520
CY2022 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-34266
CY2021 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-7905
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
533131
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
245697
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
4458578
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
2965692
CY2022 capr Debt Instrument Forgiveness Of Debt
DebtInstrumentForgivenessOfDebt
0
CY2021 capr Debt Instrument Forgiveness Of Debt
DebtInstrumentForgivenessOfDebt
318160
CY2022 capr Noncash Lease Expenses
NoncashLeaseExpenses
161740
CY2021 capr Noncash Lease Expenses
NoncashLeaseExpenses
48395
CY2022 capr Increase Decrease From Grants Receivable
IncreaseDecreaseFromGrantsReceivable
155830
CY2021 capr Increase Decrease From Grants Receivable
IncreaseDecreaseFromGrantsReceivable
391750
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-240045
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
148728
CY2022 us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
-7550
CY2021 us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
187021
CY2022 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1718312
CY2021 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
400750
CY2022 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-510154
CY2021 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
590416
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
27448531
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4916637
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16809324
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
114218737
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
82505961
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000243
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1196286
CY2022 capr Payments To Acquire Leasehold Improvements
PaymentsToAcquireLeaseholdImprovements
1359488
CY2021 capr Payments To Acquire Leasehold Improvements
PaymentsToAcquireLeaseholdImprovements
0
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35072507
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1196286
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4803534
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20174448
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
70304
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
50562
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4873838
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20225010
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-25282032
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2219400
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34885274
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32665874
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9603242
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34885274
CY2022 us-gaap Interest Paid Net
InterestPaidNet
0
CY2021 us-gaap Interest Paid Net
InterestPaidNet
0
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2022 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Reclassification</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:none;">Certain reclassification of prior period amounts has been made to conform to the current year presentation.</span></p>
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
41400000
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
34900000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
12000000.0
CY2020Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
738778
CY2021Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
738778
CY2021 capr Employee Retention Credit Cares Act Revenue
EmployeeRetentionCreditCaresActRevenue
191199
CY2022Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
547580
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</p>
CY2022 us-gaap Depreciation
Depreciation
533131
CY2021 us-gaap Depreciation
Depreciation
243532
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5769655
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2552408
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1181625
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
756712
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4588030
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1795696
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2165
CY2021 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2022 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
capr Grant Income
GrantIncome
0
CY2022 capr Miscellaneous Income
MiscellaneousIncome
0
CY2021 capr Miscellaneous Income
MiscellaneousIncome
200000
CY2022Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
73700000
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21800000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13600000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.24
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28900000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20000000.0
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
105244
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.23
CY2021Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
318160
CY2022 capr Commission Rate On Sale Price Per Share
CommissionRateOnSalePricePerShare
0.030
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25241402
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
126173
CY2020Q4 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
1.32
CY2021 capr Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
20391
CY2021 capr Class Of Warrant Or Right Exercised Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice
1.10
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2021Q4 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
1.37
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2022Q4 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
1.37
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2022Q4 capr Share Based Compensation Arrangement By Share Based Payment Award Number Of Options Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsAvailableForGrant
2603218
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.04
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.45
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.23
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.24
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.015
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.039
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.005
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.011
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4458578
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2965692
CY2022Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
5776839
CY2022Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
2.97
CY2022Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
2484287
CY2022Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
2.51
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
10100000
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y3M18D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
51044
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
867854
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5773788
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3540034
CY2022Q4 capr Number Of Financial Institutions
NumberOfFinancialInstitutions
2
CY2022Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
41100000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
798688
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
763814
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
708087
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
546138
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2816727
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
256618
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2560109
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
682039
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1878070
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2560109
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y7M2D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0518
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2300000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2600000
CY2022 capr Severance Package To Be Paid For Period Of Base Salary
SeverancePackageToBePaidForPeriodOfBaseSalary
P6M
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
30000000.0
CY2022Q1 capr Potential Milestone Payments
PotentialMilestonePayments
705000000.0
CY2022Q1 capr Upfront Payment
UpfrontPayment
30000000.0
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
30000000.0
CY2022Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2600000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
27400000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
27400000
CY2022Q4 capr Accounts Payable And Accrued Expenses Related Party Current
AccountsPayableAndAccruedExpensesRelatedPartyCurrent
89234
CY2021Q4 capr Accounts Payable And Accrued Expenses Related Party Current
AccountsPayableAndAccruedExpensesRelatedPartyCurrent
599388
CY2022 capr Compensation Receivable In Connection To Services To Be Provided
CompensationReceivableInConnectionToServicesToBeProvided
1700000
CY2021 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
245000
CY2022 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
0

Files In Submission

Name View Source Status
capr-20221231_cal.xml Edgar Link unprocessable
capr-20221231_lab.xml Edgar Link unprocessable
0001558370-23-004124-index-headers.html Edgar Link pending
0001558370-23-004124-index.html Edgar Link pending
0001558370-23-004124.txt Edgar Link pending
0001558370-23-004124-xbrl.zip Edgar Link pending
capr-20221231.xsd Edgar Link pending
capr-20221231x10k.htm Edgar Link pending
capr-20221231x10k005.jpg Edgar Link pending
capr-20221231x10k006.jpg Edgar Link pending
capr-20221231x10k007.jpg Edgar Link pending
capr-20221231x10k008.jpg Edgar Link pending
capr-20221231xex10d55.htm Edgar Link pending
capr-20221231xex21d1.htm Edgar Link pending
capr-20221231xex23d1.htm Edgar Link pending
capr-20221231xex31d1.htm Edgar Link pending
capr-20221231xex31d2.htm Edgar Link pending
capr-20221231xex32d1.htm Edgar Link pending
capr-20221231xex32d2.htm Edgar Link pending
capr-20221231xex4d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
capr-20221231_def.xml Edgar Link unprocessable
capr-20221231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
capr-20221231x10k_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending